Trabecular meshwork bypass stent demand — the Glaukos iStent inject W, iStent infinite, Alcon Hydrus Microstent, and Ivantis SUPRACOR creating 1-3 mm titanium or nitinol implants bypassing trabecular meshwork resistance into Schlemm's canal for intraocular pressure reduction in mild-to-moderate open-angle glaucoma representing the largest MIGS device segment in the global minimally invasive glaucoma surgery device market — creates the most anatomically targeted market segment, with the Minimally Invasive Glaucoma Surgery Device Market reflecting trabecular bypass as the premium outflow commercial driver.

Glaucoma disease burden and treatment gap — the approximately 80 million people globally with glaucoma, 10% bilaterally blind, 3.4 million Americans affected, and 50% undiagnosed creating the detection and treatment imperative — demonstrates the public health challenge. The trabecular meshwork generating 75-80% of conventional outflow resistance and MIGS devices reducing this resistance by 30-50% creating the physiological rationale for trabecular bypass.

iStent inject W market leadership — the Glaukos iStent inject W (two heparin-coated titanium stents, 360 µm length, 230 µm width, pre-loaded in single-use injector) creating FDA-approved standalone (2018) and combined with cataract surgery (2018) indications with 7-8 mmHg IOP reduction and 20-30% medication reduction in pivotal trials — demonstrates the clinical validation. The iStent infinite (three stent system for standalone, extended follow-up) and worldwide implantation exceeding 1 million units creating the market scale.

Hydrus Microstent and 90-degree canal scaffolding — the Alcon Hydrus Microstent (8 mm nitinol intracanalicular scaffold, 24-gauge delivery, 90-degree canal coverage) creating sustained Schlemm's canal dilation and collector channel access with 7-9 mmHg IOP reduction and 40-50% medication reduction — demonstrates the scaffolding innovation. The Hydrus III study demonstrating non-inferiority to selective laser trabeculoplasty (SLT) and superiority in medication reduction creating the comparative evidence.

Do you think trabecular bypass MIGS will eventually replace medication as first-line therapy for mild-to-moderate glaucoma, or will the cost, invasive nature, and established efficacy of prostaglandin analogs maintain medical therapy as initial treatment with MIGS as escalation after failure?

What trabecular bypass MIGS devices are available? Glaukos iStent family: iStent inject W — Two stents, titanium, heparin-coated; 360 µm length, 230 µm width; Pre-loaded injector; FDA: combined with cataract (2018), standalone (2018); IOP reduction: 7-8 mmHg; Medication reduction: 20-30%; iStent infinite — Three stent system; Standalone indication; Extended follow-up; iStent inject — Predecessor, single stent; Alcon Hydrus Microstent: 8 mm nitinol scaffold; 24-gauge delivery; 90-degree canal coverage; Intracanalicular placement; FDA: combined with cataract (2018); IOP reduction: 7-9 mmHg; Medication reduction: 40-50%; Non-inferior to SLT (Hydrus III); Ivantis SUPRACOR: 8 mm nitinol; Similar to Hydrus; CE marked; US clinical trials; Other trabecular devices: iStent Supra — suprachoroidal, Glaukos; SOLX Gold Shunt — suprachoroidal; Trabectome — trabecular ablation, NeoMedix; Kahook Dual Blade — trabecular incision, New World Medical; OMNI — viscodilation + trabeculotomy, Sight Sciences; Key specifications: Material: Titanium (iStent), nitinol (Hydrus, SUPRACOR); Coating: Heparin (iStent), none (Hydrus); Delivery: Pre-loaded injector (iStent); Manual insertion (Hydrus); Size: 230-360 µm (iStent); 8 mm length (Hydrus); Canal coverage: 60-90 degrees; Procedure: Phacoemulsification + MIGS (combined); Standalone (iStent infinite, Hydrus); Time: 5-10 minutes additional; Anesthesia: Topical, intracameral; Outcomes: IOP: 15-18 mmHg (target); 7-9 mmHg reduction; Medications: 0-1 drops (target); 20-50% reduction; Success: 70-80% at 2 years; Complications: Stent malposition: 5-10%; Corneal touch: 2-5%; IOP spike: 10-15%; Hyphema: 5-10%; Infection: <1%.

What is the market size and cost structure for trabecular bypass MIGS? Market metrics: Global MIGS device market: $800 million-1.2 billion (2024); Trabecular bypass: 50-55% ($400-660 million); Suprachoroidal: 15-20%; Subconjunctival: 20-25%; Ab interno cyclophotocoagulation: 5-10%; Growth: 12-15% CAGR; Pricing: iStent inject W: $1,200-1,500 per unit; Hydrus Microstent: $1,500-2,000; iStent infinite: $2,000-2,500; Procedure cost: $3,000-6,000 (surgeon + facility); Reimbursement: CPT 0191T — iStent inject; $800-1,200 physician fee; Facility: $2,000-4,000; Medicare: covered; Commercial: variable, prior auth; Key suppliers: Glaukos — iStent, market leader, 40-45%; Alcon — Hydrus, 20-25%; Ivantis — SUPRACOR, 5-8%; Sight Sciences — OMNI, 8-10%; NeoMedix — Trabectome, 3-5%; New World Medical — Kahook, 3-5%; Others — 5-10%; Market drivers: Glaucoma prevalence, aging population, cataract surgery volume, medication non-adherence, safety profile, reimbursement expansion, patient preference, surgeon adoption; Challenges: Cost, reimbursement variability, long-term durability, learning curve, patient selection, competition with SLT, medication persistence, combined vs. standalone; Trends: Standalone expansion, multiple stents, personalized MIGS, AI patient selection, sustained drug delivery, bioabsorbable implants, 3D printing, telemedicine follow-up.

#MIGS #MinimallyInvasiveGlaucomaSurgery #iStent #Hydrus #TrabecularBypass #Glaucoma #SchlemmCanal #IOPReduction #Glaukos #Alcon